Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGSWW) Operating Expenses (2020 - 2025)

GeneDx Holdings has reported Operating Expenses over the past 6 years, most recently at $71.4 million for Q4 2025.

  • Quarterly results put Operating Expenses at $71.4 million for Q4 2025, up 79.67% from a year ago — trailing twelve months through Dec 2025 was $222.8 million (up 48.33% YoY), and the annual figure for FY2025 was $222.8 million, up 48.33%.
  • Operating Expenses for Q4 2025 was $71.4 million at GeneDx Holdings, up from $64.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for WGSWW hit a ceiling of $155.2 million in Q1 2021 and a floor of $24.8 million in Q2 2021.
  • Median Operating Expenses over the past 5 years was $52.7 million (2021), compared with a mean of $59.2 million.
  • Peak annual rise in Operating Expenses hit 296.8% in 2022, while the deepest fall reached 56.17% in 2022.
  • GeneDx Holdings' Operating Expenses stood at $80.2 million in 2021, then dropped by 15.74% to $67.6 million in 2022, then tumbled by 34.68% to $44.1 million in 2023, then fell by 10.01% to $39.7 million in 2024, then skyrocketed by 79.67% to $71.4 million in 2025.
  • The last three reported values for Operating Expenses were $71.4 million (Q4 2025), $64.3 million (Q3 2025), and $42.5 million (Q2 2025) per Business Quant data.